Aurora Cannabis (NYSE: ACB) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Aurora Cannabis to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.
Valuation & Earnings
This table compares Aurora Cannabis and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aurora Cannabis||$207.89 million||-$2.47 billion||-1.41|
|Aurora Cannabis Competitors||$218.50 million||-$99.79 million||1.73|
Risk & Volatility
Aurora Cannabis has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Aurora Cannabis’ rivals have a beta of 2.56, indicating that their average share price is 156% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Aurora Cannabis and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aurora Cannabis Competitors||136||361||413||14||2.33|
Aurora Cannabis presently has a consensus price target of $14.03, indicating a potential upside of 249.09%. As a group, “Medicinals & botanicals” companies have a potential upside of 97.62%. Given Aurora Cannabis’ higher probable upside, research analysts clearly believe Aurora Cannabis is more favorable than its rivals.
This table compares Aurora Cannabis and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aurora Cannabis Competitors||-163.69%||-267.59%||-46.37%|
Insider & Institutional Ownership
11.5% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Aurora Cannabis rivals beat Aurora Cannabis on 10 of the 13 factors compared.
Aurora Cannabis Company Profile
Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company's products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. As of February 26, 2019, the company had operations in 24 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies. The company has a strategic agreements with Hempco Food and Fiber Inc.; CTT Pharmaceuticals Inc.; Choom Holdings Inc.; Capcium Inc.; The Green Organic Dutchman Holdings Ltd.; Société des Alcools du Québec; Alcanna; Radient Technologies; Micron Waste; Wagner Dimas; Evio; and Cann Group Limited. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.